Share This Page
Suppliers and packagers for methylin
✉ Email this page to a colleague
methylin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | METHYLIN | methylphenidate hydrochloride | SOLUTION;ORAL | 021419 | NDA | SHIONOGI INC. | 59630-750-50 | 500 mL in 1 BOTTLE (59630-750-50) | 2002-12-19 |
| Specgx Llc | METHYLIN | methylphenidate hydrochloride | SOLUTION;ORAL | 021419 | NDA | SHIONOGI INC. | 59630-755-50 | 500 mL in 1 BOTTLE (59630-755-50) | 2002-12-19 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: METHYLIN
Introduction
Methylin, a trademarked formulation of methylphenidate, is a central nervous system stimulant primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy. As a controlled substance, methylin’s supply chain involves strict regulatory oversight, involving authorized manufacturers, distributors, and pharmacies. Understanding the key suppliers for methylin is critical for healthcare providers, pharmaceutical companies, and policymakers aiming to ensure a stable, compliant supply chain.
Overview of Methylin and Its Market
Methylin is marketed by corporate entities such as Mallinckrodt Pharmaceuticals, which holds the rights for certain formulations, and potentially by other generic manufacturers post-patent expiration. It exists in various formulations, including immediate-release tablets and oral solutions, accommodating diverse patient needs. The global methylphenidate market, including methylin, is driven by rising ADHD prevalence and improved awareness, fostering demand for both branded and generic products.
The global market for methylphenidate, and by extension methylin, is tightly regulated under drug control laws, such as the Controlled Substances Act in the United States, due to its psychoactive potential. This regulatory environment narrows the pool of legitimate suppliers, emphasizing the role of licensed manufacturers with explicit drug manufacturing licenses.
Key Manufacturers and Suppliers of Methylin
1. Mallinckrodt Pharmaceuticals
Mallinckrodt is perhaps the most recognized manufacturer of methylin, particularly its branded formulations. As a leading pharmaceutical entity in the stimulant market, Mallinckrodt manufactures methylin in the United States under strict FDA regulations. The company also produces specialized formulations such as methylin ER (extended-release), with distribution channels that include licensed pharmacies and healthcare providers nationwide.
2. Pfizer Inc.
Historically, Pfizer has been a prominent supplier of methylphenidate formulations, including methylin, before divestitures and restructuring. Certain formulations historically marketed by Pfizer continue to be available through generic manufacturers. Pfizer’s high regulatory standards ensure compliance and quality in its supply chain.
3. Teva Pharmaceutical Industries Ltd.
Teva is among the leading global generic pharmaceutical companies, manufacturing methylphenidate-based products, including methylin equivalents. Teva’s extensive production facilities and distribution network enable it to serve extensive markets, including the United States and Europe.
4. Sandoz (Novartis)
A prominent generic manufacturer, Sandoz produces methylphenidate formulations similar to methylin. Sandoz’s global footprint and reputation for quality establish it as a significant supplier, particularly in countries where generic methylphenidate is preferred.
5. Other Generic Manufacturers
Additional manufacturers, such as Mylan (now part of Viatris), Greenstone (a subsidiary of Pfizer), and Apotex, manufacture methylphenidate formulations, many of which can be considered methylin equivalents, supplied through licensed distribution channels.
Regulatory and Distribution Channels
Regulatory Oversight
All suppliers of methylin operate under strict oversight from agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and comparable authorities worldwide. They are required to adhere to Good Manufacturing Practices (GMP), undergo regular inspections, and maintain comprehensive compliance records.
Distribution Network
Suppliers distribute methylin through licensed pharmacies, hospitals, and specialty clinics. Distribution channels are tightly controlled to prevent diversion and misuse, often involving secure logistics, serial number tracking, and adherence to Schedule II substance regulations.
Supply Challenges and Considerations
The supply chain for methylin faces unique challenges related to:
- Regulatory restrictions: Stringent controls limit the number of qualified manufacturers.
- Manufacturing complexities: The formulation requires precise control of pharmacological properties to ensure efficacy and safety.
- Global supply disruptions: Political, regulatory, or manufacturing issues can affect the consistency of supply.
- Patent and exclusivity periods: The expiration of patents has broadened the supplier base but has also introduced variability.
Emerging Trends and Strategic Implications
- Generic proliferation: Increased manufacturing by generic firms after patent expiry has diversified the supplier landscape but raises concerns about quality assurance and regulatory compliance.
- Supply chain resilience: Manufacturers are investing in redundancy and strategic stockpiles to mitigate shortages.
- International markets: Suppliers are expanding into emerging markets, where demand for methylphenidate formulations like methylin is rising, adding complexity to the global supply network.
Key Takeaways
- Major suppliers include Mallinckrodt, Teva, Sandoz, and other generics, most operating under strict regulatory oversight.
- The supply chain for methylin is tightly regulated to prevent diversion, with distribution limited to licensed channels.
- Global supply disruptions can impact availability; strategic stockpiling and diversified manufacturing are key mitigants.
- Patent expirations have broadened the supplier base but increased the importance of quality assurance.
- Stakeholders should stay vigilant to regulatory changes impacting manufacturing and distribution.
FAQs
1. Who are the primary manufacturers of methylin?
Mallinckrodt Pharmaceuticals is the primary branded manufacturer; other major providers include Teva, Sandoz, and additional generic producers like Mylan.
2. Is methylin available from international suppliers?
Yes. While primarily produced in the U.S. and Europe, international generic firms supply methylphenidate formulations in various markets, subject to local regulations.
3. How do supply chain regulations affect the availability of methylin?
Strict regulation under controlled substance laws limits the number of authorized manufacturers and distributors, thus impacting overall supply stability.
4. Are there risks of shortages or diversion in methylin supply?
Yes, due to regulatory constraints, manufacturing complexities, and potential disruptions. However, manufacturers and regulators implement safeguards to minimize these risks.
5. Can I obtain methylin through online or unlicensed channels?
No. Procuring methylin outside licensed pharmacies is illegal and poses significant safety and legal risks.
Sources
- U.S. Food and Drug Administration (FDA). “Drug Approvals and Labeling.” https://www.fda.gov.
- MarketWatch. “Global Methylphenidate Market Analysis.” 2022.
- IMS Health (IQVIA). “Pharmaceutical Market Reports.” 2022.
- European Medicines Agency. “Marketing authorization of methylphenidate formulations.” 2022.
- Pharmaceutical manufacturer websites and annual reports.
Conclusion
The methylin supply chain revolves around a handful of well-regulated, licensed manufacturers, predominantly Mallinckrodt, Teva, Sandoz, and multiple generics. Ensuring medication availability requires ongoing vigilance over regulatory compliance, manufacturing capacity, and distribution integrity. As demand for ADHD treatments continues to grow globally, strategic sourcing and adherence to strict compliance standards will remain vital for stakeholders involved in methylin’s production and distribution.
More… ↓
